Introduction {#sec1-1}
============

Carotid intima-media thickness (CIMT) and atherosclerotic plaques are reliable markers of subclinical atherosclerosis and cardiovascular events ([@ref1]). Traditional risk factors, such as age, diabetes, systolic blood pressure, high-density lipoprotein (HDL) cholesterol (low levels), and LDL cholesterol, are associated with CIMT according to cross-sectional studies ([@ref2]). However, Rosvall et al. ([@ref3]) showed that predictive power of baseline low-density lipoprotein (LDL) cholesterol attenuated with increased intima-media thickness and high CIMT progression rate. An individualized approach for detection of subclinical atherosclerosis can be achieved by using novel risk factors and biomarkers such as epicardial adipose tissue (EAT) ([@ref4]).

Epicardial adipose tissue is a kind of visceral adipose tissue enclosed within the pericardial cavity. It has many protective roles, such as uptake of excess free fatty acids ([@ref5]) and anti-inflammatory and anti-atherosclerotic effects, mainly mediated via adiponectin ([@ref4]). In visceral obesity, EAT undergoes conformational and functional changes such that it begins to secrete pro-inflammatory and pro-atherogenic adipokines (e.g., interleukin-6, tumor necrosis factor a, adiponectin, leptin, and plasminogen activator inhibitor) ([@ref6]). EAT itself is a marker for future cardiovascular events independent of CIMT/carotid plaque ([@ref7], [@ref8]). Incorporating EAT to models comprised of traditional risk factors may pave the way for a better understanding of factors affecting CIMT. Until today, there was no study that investigated whether epicardial adipose tissue (EAT), which is a surrogate for lipid depot in a special visceral tissue or circulating lipids, is more important for CIMT and atherosclerotic plaque. Therefore, our primary aim is to evaluate the associations of traditional risk factors, including circulating lipids and visceral adipose tissue, with CIMT and the plaque.

Methods {#sec1-2}
=======

Patient population and study protocol {#sec2-1}
-------------------------------------

Our study, having cross-sectional and prospective observational design, included 252 patients who were admitted to our outpatient clinic of the Rize University, Department of Cardiology, Rize, Turkey. Patients with hypertension, diabetes mellitus, and hyperlipidemia were selected for the study. Any previous history of coronary artery disease (CAD), left ventricular systolic dysfunction, and moderate to severe valve disease were accepted as exclusion criteria. We also excluded any patient with symptoms suggestive of CAD, which was confirmed by relevant findings with exercise ECG and perfusion scan. By the exclusion criterion, we aimed to decrease the number of confounding factors and to provide homogeneity in our study.

The patients were evaluated in terms of age, demographical properties, and cardiovascular risk factors. Hypertension was described as the active use of antihypertensive drugs or confirmation of blood pressure more than 140/90 mm Hg. Diabetes mellitus (DM) was described as fasting plasma glucose levels over 126 mg/dL. Also, plasma glucose level over 200 mg/dL at any measurement or active use of antidiabetic treatment was accepted as DM. Dyslipidemia was defined as fasting blood total cholesterol \>200 mg/dL, fasting blood low-density lipoprotein levels \>130 mg/dL, or previously receiving anti-hyperlipidemic medication. Patients who were using tobacco products on admission to our hospital and those who quit smoking within the last year were considered smokers. The family history for CAD was defined as a history of CAD or sudden death in a first-degree relative before the age of 55 years for men and 65 years for women.

Informed consent was obtained from all patients prior to the study. This study was performed in accordance with the principles stated in the Declaration of Helsinki and approved by the local Ethics Committee.

Routine measurements {#sec2-2}
--------------------

Blood samples were drawn by venipuncture to measure routine blood chemistry parameters after fasting for at least 8 hours. Glucose, creatinine, and lipid profile were determined by standard methods. Fasting blood glucose, serum creatinine, uric acid levels, total cholesterol, HDL cholesterol, and triglyceride levels were recorded (UniCel DxC 800, Beckman Coulter USA). The Friedewald's formula was used for LDL cholesterol measurement ([@ref9]). When triglyceride level exceeded 400 mg/dL, the direct measurement technique was used for LDL measurement (*used for 14 patients*). Serum C-reactive protein (CRP) was analyzed using a nephelometric technique (Beckman Coulter Immage 800; Fullerton, CA, USA; normal range 0--0.8 mg/dL).

Anthropometric measurements {#sec2-3}
---------------------------

Weight and height were measured while the subjects were in fasting state and wearing only their undergarments. Body mass index (BMI) was determined by the following formula: BMI=weight (kg)/height[@ref2] (m). Waist circumference (in centimeters; circumference between the lower rib margin and the iliac crest, midwaist) was measured while the subjects were standing with their heels together. These variables were used as linear variable in analyses, because their cut-off levels can change by time and population.

Echocardiography {#sec2-4}
----------------

Patients were imaged in the left lateral decubitus position by two experienced cardiologists using commercially available systems with a GE-Vingmed Vivid S5 (GE-Vingmed Ultrasound AS, Horten, Norway) according to echocardiography guidelines ([@ref10]).

Evaluation of epicardial adipose tissue {#sec2-5}
---------------------------------------

Epicardial adipose tissue was assessed on the free wall of right ventricle from the parasternal long-axis view, using aortic annulus as an anatomic reference. We magnified each image for better visualization and precise measurement of EAT thickness and measured the thickest point of EAT in each cycle. The area of above the right ventricle to measure EAT thickness was preferred, because this area is known to have the thickest EAT layer. EAT was measured perpendicularly in front of the right ventricular free wall at end-systole ([@ref11], [@ref12]) and was identified as an echo-free space under the pericardial layer on two-dimensional echocardiography ([Fig. 1](#F1){ref-type="fig"}). The average value comprising three cardiac cycles of each echocardiographical view was used for the statistical analysis. Inter-observer and intra-observer variability on epicardial fat thickness measurement was excellent: coefficients of correlation were 0.94 and 0.98, respectively.

![Evaluation of epicardial adipose tissue\
EAT - identified as an echo-free space between the myocardium and visceral pericardium from the parasternal long-axis view on two-dimensional echocardiography, was measured perpendicularly in front of the right ventricular free wall at end-systole](AJC-17-56-g001){#F1}

Measurement of carotid intima-media thickness {#sec2-6}
---------------------------------------------

Measurements were performed for the right and left carotid arteries ([@ref13]). The patient was lying supine, the head directed away from the side of interest, and the neck slightly extended. The transducer was manipulated so that the near and far walls of the common carotid artery were parallel, and the lumen diameter was maximized in the longitudinal plane. The region 1 cm proximal to the carotid bifurcation was identified, and the CIMT of the far wall was evaluated as the distance between the lumen--intima interface and the media--adventitia interface. The CIMT was measured on the frozen frame of a suitable longitudinal image, with the image magnified to achieve a higher resolution of detail. The CIMT measurement was obtained from four contiguous sites at 1 mm intervals, and the average of all eight measurements was used for analyses. Ultrasonography was performed on all patients using a high-resolution ultrasonography scanner (VingMed Vivid 3, GE Medical System, Horten, Norway) with a 7.0 MHz linear array transducer.

A carotid intima-media thickness lower than 0.9 mm was considered normal; a thickness higher than 0.9 mm but lower than 1.3 was considered increased; a thickness higher than 1.3 mm was defined as a plaque ([@ref14]). We also checked 1.5 mm cut-off of CIMT, which is the last definition in the ESC guideline, but similar results were achieved ([@ref15]).

Statistical analysis {#sec2-7}
--------------------

Continuous variables were given as mean±SD; categorical variables were defined as percentages. Data were tested for normal distribution using the Kolmogorov-Smirnov test. Only CRP was non-normally distributed. It is given as median (range). We performed logarithmical transformation to normalize CRP and presented this form additionally. Spearman's rank correlation coefficient was used to analyze the relationship between the variables. Mean values were compared by ANOVA followed by the Tukey's HSD test among different groups. Multiple logistic and linear regression analyses were used to assess multivariate relations among CIMT and carotid plaque, EAT, LDL, HDL, and various variables. In these analyses, a stepwise method for all independent variables were used, including age, gender, waist circumference, body mass index, diabetes, hypertension, dyslipidemia, family history of CAD, smoking status, lipids, EAT, alanine aminotransferase, gamma-glutamyl transferase, CRP, leukocytes (including monocyte), bilirubins, uric acid, creatinine, glucose, and hemoglobin levels. After first pre-elimination, linear and logistic regression analyses with enter method were repeated for independent variables, which were included if they were significantly different in the univariate analyses. The last elimination analysis was repeated with stepwise method for the previous significant determined variables.

Statistical significance was defined as p\<0.05. All tests of significance were two-tailed. The SPSS statistical software (SPSS for windows, version 15.0, Inc., Chicago, IL, USA) was used for all statistical calculations.

Results {#sec1-3}
=======

Clinical characteristics of the patients are presented in [Table 1](#T1){ref-type="table"}. Our study included 252 patients (mean age: 46±8 years) with a male preponderance (71%). Correlations of EAT, LDL, HDL, and CIMT to other study parameters is detailed in [Table 2](#T2){ref-type="table"}.

###### 

Baseline demographics and clinical characteristics of study population

  Variables                    Patients (n=252)
  ---------------------------- ------------------
  Age, years                   46±8
  Gender, male                 71%
  BMI, kg/m^2^                 30.4±4.7
  Waist circumference, cm      101±11
  Hypertension                 65%
  Diabetes mellitus            8%
  Smoking status               20%
  Dyslipidemia                 35%
  Family history of CAD        45%
  Glucose, mg/dL               103±31
  Creatinine, mg/dL            0.84±0.16
  Uric acid, mg/dL             5.3±1.5
  T. Bilirubin, mg/dL          0.81±0.45
  Total cholesterol, mg/dL     216±41
  LDL-cholesterol, mg/dL       136±36
  HDL-cholesterol, mg/dL       45±12
  Triglycerides, mg/dL         176±121
  CRP, mg/dL, median/range     0.32 (3.96)
  CRP, log-transformed         -0.46±0.33
  ALT, U/L                     28±20
  GGT activity, U/L            32±22
  Leukocytes, 10^3^/mm^3^      7.6±1.8
  Hemoglobin, g/dL             14.5±1.5
  Platelets, 10^3^/mm^3^       280±64
  CIMT, mm, mean               0.81±0.17
  Presence of carotid plaque   18%
  EAT, mm                      5.8±2.5

ALT - alanine aminotransferase; BMI - body mass index; CAD - coronary artery disease; CIMT - carotid intima-media thickness; CRP - C-reactive protein; EAT - epicardial adipose tissue thickness; GGT - gamma-glutamyl transferase; HDL - high density lipoprotein; LDL - low density lipoprotein. Continuous variables were given as mean±SD; categorical variables were defined as percentages

###### 

Correlations of epicardial adipose tissue and serum lipids with study parameters

                             EAT, mm   LDL, mg/dL   HDL, mg/dL   CIMT, mm, mean                               
  -------------------------- --------- ------------ ------------ ---------------- -------- --------- -------- ---------
  Age, years                 0.259     \<0.001      0.283        \<0.001          0.168    0.001     0.467    \<0.001
  BMI, kg/m^2^               0.229     \<0.001      0.068        0.174            0.018    0.713     0.106    0.031
  Waist circumference, cm    0.539     \<0.001      -0.035       0.536            -0.184   0.001     0.358    \<0.001
  Glucose, mg/dL             0.016     0.888        0.044        0.382            0.029    0.556     0.135    0.007
  Creatinine, mg/dL          0.178     0.007        -0.010       0.845            -0.290   \<0.001   0.176    0.001
  T. Bilirubin, mg/dL        -0.075    0.262        -0.051       0.340            0.104    0.045     -0.079   0.130
  Uric acid, mg/dL           0.298     \<0.001      0.125        0.015            -0.288   \<0.001   0.284    0.001
  Total cholesterol, mg/dL   0.101     0.121        0.843        \<0.001          0.155    0.002     0.087    0.083
  LDL-cholesterol, mg/dL     0.099     0.132        --           --               0.177    \<0.001   0.138    0.007
  HDL-cholesterol, mg/dL     -0.132    0.043        0.154        0.002            --       --        -0.095   0.060
  Triglycerides, mg/dL       0.133     0.041        -0.093       0.062            -0.482   \<0.001   0.059    0.241
  LDL/HDL ratio              0.150     0.022        --           --               --       --        0.163    0.001
  TK/HDL ratio               0.181     0.005        --           --               --       --        0.135    0.007
  CRP, mg/dL                 0.322     \<0.001      0.191        \<0.001          -0.032   0.546     0.234    \<0.001
  CRP, log-transformed       0.349     \<0.001      0.189        \<0.001          -0.021   0.697     0.215    \<0.001
  ALT, U/L                   0.150     0.021        0.090        0.079            -0.188   \<0.001   0.065    0.198
  GGT activity, U/L          0.198     0.003        0.058        0.275            -0.300   \<0.001   0.158    0.003
  Leukocytes, /mm^3^         0.057     0.388        -0.010       0.851            -0.232   \<0.001   0.035    0.498
  Monocyte, /mm^3^           0.119     0.070        -0.027       0.595            -0.197   \<0.001   0.129    0.012
  Hemoglobin, g/dL           0.110     0.094        -0.027       0.607            -0.326   \<0.001   0.167    0.001
  Platelets, 10^3^/mm^3^     0.096     0.148        0.051        0.323            0.059    0.244     -0.057   0.269
  EAT, mm                    --        --                                                            0.623    \<0.001
  CIMT, mm, mean             0.623     \<0.001      0.138        0.007            -0.095   0.060     --       --
  Right, mm                  0.612     \<0.001      0.133        0.010            -0.090   0.073     --       --
  Left, mm                   0.630     \<0.001      0.122        0.017            -0.106   0.035     --       --

ALT - alanine aminotransferase; BMI - body mass index; CIMT - carotid intima-media thickness; CRP - C-reactive protein; EAT - epicardial adipose tissue thickness; GGT - gamma-glutamyl transferase; HDL - high density lipoprotein; LDL - low density lipoprotein, TK - total cholesterol.

Pearson&Spearmen tests were used to analyze the relationship between EAT and study variables where appropriate

Epicardial adipose tissue significantly correlated to CIMT (r=0.623, p\<0.001), as well as age, BMI, waist circumference, creatinine, uric acid, and CRP. CIMT correlated to age, waist circumference, uric acid, CRP, and EAT ([Table 2](#T2){ref-type="table"}). CIMT was significantly increased with rising EAT thickness (0.72±0.15 mm, 0.85±0.16 mm, and 0.95±0.12 mm in patients with EAT \<5, 5--7, and \>7 mm, p\<0.001, respectively) ([Table 3](#T3){ref-type="table"}).

###### 

The distributions of study parameters according to EAT subgroups

  Variables                  EAT (\<5 mm) (n=119)   EAT (5--7 mm) (n=70)                         EAT (\>7 mm) (n=63)                                                           *P[\*](#t3f1){ref-type="table-fn"}*
  -------------------------- ---------------------- -------------------------------------------- ----------------------------------------------------------------------------- -------------------------------------
  Age, years                 46±8                   50±8^[a](#t3f2){ref-type="table-fn"}^        50±9^[a](#t3f2){ref-type="table-fn"}^                                         **0.009**
  Gender, male               50%                    63%                                          63%                                                                           0.094
  BMI, kg/m^2^               30.7±5.0               30.1±3.4                                     33.7±4.3^[a](#t3f1){ref-type="table-fn"},[b](#t3f2){ref-type="table-fn"}^     **\<0.001**
  WC, cm                     96.7±10.3              100.4±7.9^[a](#t3f2){ref-type="table-fn"}^   110.7±9.0^[a](#t3f1){ref-type="table-fn"},[b](#t3f2){ref-type="table-fn"}^    **\<0.001**
  Hypertension               82%                    84%                                          87%                                                                           0.709
  Diabetes mellitus          8%                     1%                                           2%                                                                            **0.019**
  Smoking status             22%                    15%                                          24%                                                                           0.367
  Dyslipidemia               27%                    35%                                          40%                                                                           0.160
  Family history of CAD      67%                    44%                                          53%                                                                           0.081
  Glucose, mg/dL             101±19                 100±16                                       99±14                                                                         0.818
  Creatinine, mg/dL          0.81±0.22              0.84±0.13                                    0.80±0.10                                                                     0.537
  Uric acid, mg/dL           4.8±1.4                5.3±1.4                                      5.7±1.4^[a](#t3f2){ref-type="table-fn"}^                                      **\<0.001**
  T. Bilirubin, mg/dL        0.95±0.59              0.80±0.42                                    0.77±0.32                                                                     0.051
  Total cholesterol, mg/dL   215±39                 219±38                                       227±41                                                                        0.158
  LDL-cholesterol, mg/dL     137±31                 140±35                                       145±35                                                                        0.302
  HDL-cholesterol, mg/dL     47±14                  47±11                                        45±9                                                                          0.430
  Triglycerides, mg/dL       157±81                 159±116                                      184±107                                                                       0.211
  LDL/HDL ratio              3.09±1.02              3.06±0.84                                    3.33±0.95                                                                     0.211
  TK/HDL ratio               4.83±1.36              4.87±1.25                                    5.22±1.22                                                                     0.159
  CRP, mg/dL                 0.41±0.41              0.47±0.43                                    0.67±0.57^[a](#t3f1){ref-type="table-fn"},[b](#t3f2){ref-type="table-fn"}^    **0.001**
  CRP, log-transformed       -0.53±0.33             -0.46±0.32                                   -0.27±0.30^[a](#t3f1){ref-type="table-fn"},[b](#t3f2){ref-type="table-fn"}^   **\<0.001**
  ALT, U/L                   26±17                  27±19                                        29±19                                                                         0.490
  GGT activity, U/L          30±22                  29±19                                        34±16                                                                         0.433
  Leukocytes, 10^3^/mm^3^    7.4±2.1                7.3±1.4                                      7.5±1.7                                                                       0.896
  Hemoglobin, g/dL           14.0±1.8               14.5±1.3                                     14.4±1.5                                                                      0.157
  Platelets, 10^3^/mm^3^     279±57                 278±62                                       292±66                                                                        0.368
  CIMT, mm, mean             0.72±0.15              0.85±0.16^[a](#t3f2){ref-type="table-fn"}^   0.95±0.12^[a](#t3f1){ref-type="table-fn"},[b](#t3f2){ref-type="table-fn"}^    **\<0.001**
  PCP                        7%                     19%                                          41%                                                                           **\<0.001**
  Medications                                                                                                                                                                  
   Acetylsalicylic acid      15%                    20%                                          11%                                                                           0.625
   Antilipemic agents        9%                     5%                                           13%                                                                           0.135
   Antihypertensive drugs    50%                    60%                                          67%                                                                           0.895
   Antidiabetic drugs        6%                     3%                                           2%                                                                            0.456

ALT - alanine aminotransferase; BMI - body mass index; CAD - coronary artery disease; CIMT - carotid intima-media thickness; CRP - C-reactive protein; GGT - Gamma-glutamyl transferase; HDL-C - high-density lipoprotein cholesterol; LDL - Low-density lipoprotein cholesterol; PCP - presence of carotid plaque; TK - total cholesterol, waist circumference.

Mean values were compared by analysis of variance (ANOVA) followed by the Tukey's HSD test among different EAT groups.

When compared with EAT \<5 mm, *P*\<0.05.

When compared with EAT 5--7 mm, *P*\<0.05

Multiple linear regression analysis revealed age (Beta: 0.406, p\<0.001), male gender (Beta: 0.244, p\<0.001), and EAT (Beta: 0.450, p\<0.001) as independent correlates of CIMT. Otherwise, in logistic regression analysis, only EAT (OR, 1.386; 95% CI, 1.203--1.597, p\<0.001) and LDL (OR, 1.013; 95% CI, 1.002--1.013, p=0.02) were independent predictors for presence of carotid plaque ([Table 4](#T4){ref-type="table"}).

###### 

Linear and logistic regression analyses were used for prediction of CIMT and presence of carotid plaque

  Linear regression analysis         Dependent variable: Carotid intima-media thickness                                                           
  ---------------------------------- ---------------------------------------------------- ---------- ---------------------- ---------- ---------- ----------------------
  Age, years                         \<0.001                                              0.476      0.010±0.001            \<0.001    0.406      0.008±0.001
  Gender, male                       \<0.001                                              0.429      0.155±0.027            \<0.001    0.244      0.085±0.016
  Family history of CAD              0.136                                                0.096      0.035±0.023                                  
  HDL-C, mg/dL                       0.323                                                0.070      0.001±0.001                                  
  LDL, mg/dL                         0.009                                                0.161      0.001±0.000                                  
   LDL/HDL ratio                     0.294                                                0.068      0.012±0.011                                  
   TK/HDL ratio                      0.691                                                0.026      0.003±0.008                                  
  EAT, mm                            \<0.001                                              0.323      0.028±0.005            \<0.001    0.450      0.031±0.003
  Constant                           0.125                                                           -0.132±0.086           0.737                 0.191±0.045
  Adjusted R^2^                      0.571                                                0.534                                                   
  **Logistic regression analysis**   **Dependent variable: Presence of carotid plaque**                                                           
  **Independent variables**          **\**P***                                            **Wald**   **OR (95% CI)**        **†*P***   **Wald**   **OR (95% CI)**
  Age, years                         0.075                                                3.2        1.073 (0.993--1.159)                         
  Gender, male                       0.066                                                3.4        6.147 (0.890--42.5)                          
  Family history of CAD              0.141                                                2.2        2.791 (0.711--10.9)                          
  HDL-C, mg/dL                       0.491                                                0.5        1.024 (0.958--1.094)                         
  LDL, mg/dL                         0.002                                                9.1        1.034 (1.012--1.057)   0.020      5.4        1.013 (1.002--1.023)
   LDL/HDL ratio                     0.068                                                3.3        1.699 (0.963--2.988)                         
   TK/HDL ratio                      0.111                                                2.5        1.396 (0.926--2.104)                         
  EAT, mm                            0.002                                                9.7        1.634 (1.199--2.226)   \<0.001    20.4       1.386 (1.203--1.597)
  Constant                           \<0.001                                              18.5                              \<0.001    31         
  Adjusted R^2^                      0.455                                                0.203                                                   

CAD - coronary artery disease; EAT - epicardial adipose tissue thickness; HDL - high density lipoprotein; LDL - low density lipoprotein; SE - standard error. Linear and logistic regression analyses with enter method were used for all relevant independent variables that were included if they were significantly different in the univariate analyses\*. In addition, the analysis was repeated after a pre-elimination with stepwise method for the independent variables^†^

We showed that there is no increase in CIMT in spite of increasing LDL concentrations in patients with normal EAT levels (\<5 mm) compared with the patients in other EAT groups ([Fig. 2](#F2){ref-type="fig"}). Otherwise, LDL concentrations had a significant effect on presence of carotid plaque in all EAT groups ([Fig. 3](#F3){ref-type="fig"}).

![The changes in CIMT with increasing LDL concentrations among EAT groups\
There is no increase in CIMT in spite of increasing LDL concentrations in patients with normal EAT levels (\<5 mm) compared with the patients in other EAT groups](AJC-17-56-g002){#F2}

![The effect on presence of carotid plaque of LDL concentrations among EAT groups\
LDL concentrations had significantly effect on presence of carotid plaque in all EAT groups](AJC-17-56-g003){#F3}

Discussion {#sec1-4}
==========

We revealed that EAT, compared with the other risk factors, had a stronger association with CIMT. Our best of knowledge, this study is first to investigate whether EAT, which is a surrogate for lipid deposition in a special visceral tissue, or circulating lipids is more important for CIMT and atherosclerotic plaque. Age, male gender, and EAT are independent variables for predicting CIMT in our middle-aged, obese, mainly hypertensive study population. Likewise, carotid plaque was only predicted by LDL cholesterol and EAT. In addition, we revealed that the relation between LDL and CIMT was more pronounced if EAT was increased (\>5 mm). Indeed, there was no increase in CIMT in patients with normal EAT measuremets (\<5 mm) irrespective of their LDL levels. In contrast, LDL concentrations had significant association with the presence of carotid plaque in all EAT groups.

Carotid intima-media thickness is an already established risk marker for subclinical atherosclerosis ([@ref1]). Increases in CIMT thickness or carotid plaque burden are associated with increased atherosclerotic coronary artery disease event risk ([@ref16]). CIMT and carotid plaque reflect different stages of atherosclerotic process. Although CIMT represents tunica media smooth cell hypertrophy due to high sheer stress ([@ref17]), carotid plaque is a typical lesion for atherosclerosis. In the ARIC study, diabetes, current smoking, pulse pressure, and white blood cell count associated with CIMT in positive direction, but HDL cholesterol and triglyceride levels negatively correlated with CIMT ([@ref18]). The recently completed The Malmö Diet and Cancer Study revealed that age, LDL-cholesterol, systolic blood pressure, and smoking were significantly associated with increased progression rate of CIMT measured at common carotid artery, while HDL-cholesterol showed a negative association ([@ref3]). Carotid plaque had been shown to be associated with total cholesterol, systolic blood pressure, and smoking ([@ref17]). In our study, presence of the etiologic factors in progression of CIMT and carotid plaque suggested that study population characteristics are suitable with literature to compare study results. Demographic, anthropomorphic, and laboratory parameters like LDL cholesterol may only enable rough estimation of CIMT as well as coronary artery disease risk ([@ref3], [@ref16]). Rosvall et al. ([@ref3]) showed that predictive power of baseline LDL cholesterol was attenuated with increased intima-media thickness and high CIMT progression rate, and the correlation between LDL and CIMT is not linear. This finding may be related to the poor effect of LDL on CIMT, unlike the plaque. Our study findings also support this situation in which CIMT is more related to visceral lipid depot than circulatory lipids. We thought more precision is needed about what factors are responsible for progression of subclinical atherosclerosis. EAT may be an answer because it reflects individual's cumulative risk over his/her lifespan ([@ref19], [@ref20]). Epicardial adipose tissue mainly has local effects on coronary vessels ([@ref21]) and is directly associated with coronary artery disease development ([@ref22]). However, EAT also has systemic proatherogenic effects probably mediated via its proinflammatory properties and release of adipokines, including adiponectin ([@ref21], [@ref23]--[@ref25]). We did not able to measure specific adipokines levels in our study, but higher CRP levels in patients with increased EAT suggested that EAT is a possible inflammatory link between EAT and CIMT. Previous studies demonstrated that EAT has strong and independent association with CIMT ([@ref19], [@ref20], [@ref26], [@ref27]).

Epicardial adipose tissue measurement adds little time to routine echocardiographic examination ([@ref28]) and creates a huge opportunity for more appropriate selection of patients. If the patient has increased EAT thickness, he or she should be an appropriate candidate for further CIMT testing irrespective of LDL cholesterol levels. Because by the CIMT and carotid plaque measurement, almost 10% of the patients could be reclassified above what is provided by traditional risk factor calculation. This approach may also lessen the number of ever growing non-invasive imaging exams ([@ref29]).

Study limitations {#sec2-8}
-----------------

The cross-sectional nature of our study is a major limitation. Risk factors change within a given time window may be a more reliable marker for estimating the patient's subclinical atherosclerosis status. We did not evaluate incremental values of EAT measurement over CIMT/carotid plaque visualization in our study. A large randomized prospective study is certainly needed with which comparative or incremental value of CIMT/carotid plaque and EAT measurements for future cardiovascular events will be determined.

We did not provide data about visceral adipose tissue other than EAT, which can be an important contributor to our study findings. Our patients showed higher waist circumference and triglyceride levels when stratified by EAT. Based on this finding, we thought study patients had an increased visceral adipose tissue. But we prefer EAT as a surrogate for lipid depot in visceral adipose tissue.

Conclusion {#sec1-5}
==========

Our study showed that EAT has a relationship to both CIMT and carotid plaque but LDL is only independently related to carotid plaque. Therefore, we thought that EAT may have the probable role in the initiation and progression of atherosclerosis by providing continuous pro-atherogenic and pro-inflammatory stimulus. Prevention strategies aiming at decreasing EAT thickness may be a priority in an individual patient.

Our study suggested a possible role of EAT as a novel cardiovascular risk predictor. We can only speculate that EAT as in coronary calcium scoring can provide incremental information about patients for whom primary prevention strategies will more strongly be implemented.
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